Employees: 3,951
Size Tong Ren Tang Technologies (1666.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $491M, the 750th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$3.02 on 18 Nov 2026.
Performance Over six months the shares fell 19.5%, against -8.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 13.9% over the last twelve months (peer median +13.0%); the operating margin is 11.6% (peer median 6.8%).
Valuation It trades at 7.3× forward earnings against a peer median of 18.2× (2nd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.7 points below its cost of capital (7.1% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$6.45B | HK$7.03B | HK$7.87B | HK$7.48B | HK$6.97B |
| Revenue growth | — | -11% | +5% | +7% | — |
| Gross profit | HK$2.38B | HK$2.63B | HK$3.08B | HK$3.11B | HK$2.99B |
| EBITDA | HK$1.12B | HK$1.23B | HK$1.38B | HK$1.54B | HK$1.71B |
| Net income | HK$347M | HK$430M | HK$566M | HK$652M | HK$678M |
| Free cash flow | HK$1.32B | HK$1.63B | -HK$78.6M | HK$594M | HK$703M |
| Capital expenditure | HK$112M | HK$140M | HK$233M | HK$119M | HK$201M |
| Total debt | n/a | HK$2.42B | HK$2.79B | HK$1.79B | HK$1.79B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1666.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.7% | -0.8% | 9th lowest of 21 |
| 6-month return | -19.5% | -8.8% | 9th lowest of 21 |
| Distance from 52-week high | -39.0% | -35.5% | 10th lowest of 21 |
| Revenue growth (TTM) | -13.9% | +13.0% | lowest of 20 |
| Operating margin | 11.6% | 6.8% | 6th highest of 20 |
| Forward P/E | 7.3× | 18.2× | 2nd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -17.2% | 5.9% | least demanding of 8 |
| Growth delivered (Del g) | +6.3% | +4.4% | 4th highest of 8 |
| Hurdle (Req g minus delivered) | -23.5 pp | +4.3 pp | 2nd least demanding of 8 |
| ROIC minus cost of capital | -1.7 pp | -3.0 pp | 7th highest of 17 |
| EV / EBITDA | 3.3× | 19.2× | cheapest of 5 |
| Net debt / EBITDA | -3.0× | 1.8× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 4.1× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | n/a | 16.7% | +4.4% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | n/a | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |